Advice
in the absence of a submission from the holder of the marketing authorisation
ceftazidime/avibactam (Zavicefta®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of the following infections in adults:
• complicated intra-abdominal Infection (cIAI)
• complicated urinary tract infection (cUTI), including pyelonephritis
• hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP)
• infections due to aerobic Gram-negative organisms in adult patients with limited treatment options
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice55KB (PDF)
Medicine details
- Medicine name:
- ceftazidime avibactam (Zavicefta)
- SMC ID:
- 1307/18
- Indication:
- Treatment of the following infections in adults: • complicated intra-abdominal Infection (cIAI) • complicated urinary tract infection (cUTI), including pyelonephritis • hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) • infections due to aerobic Gram-negative organisms in adult patients with limited treatment options
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Infections
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 15 January 2018